|
|||||
|
|
| 重组人血管内皮抑素联合FOLFOX4方案治疗晚期胃肠道恶性肿瘤的临床观察 | |
| 引用本文： | 王妹兴,蔡飏,樊宏斌,戴月娣,陶莉,左丽. 重组人血管内皮抑素联合FOLFOX4方案治疗晚期胃肠道恶性肿瘤的临床观察[J]. 实用临床医药杂志, 2011, 15(5): 8-11,14 |
| 作者姓名： | 王妹兴 蔡飏 樊宏斌 戴月娣 陶莉 左丽 |
| 作者单位： | 复旦大学附属肿瘤医院闵行分院,肿瘤内科,上海,200240 |
| 基金项目： | 上海市闵行区科委资助项目 |
| 摘 要： | 目的观察重组人血管内皮抑素(恩度,YH-16)联合FOLFOX4方案治疗晚期胃肠道恶性肿瘤的近期疗效和安全性。方法经病理组织学或细胞学检查确诊的晚期胃肠道恶性肿瘤患者40例,其中胃癌18例,大肠癌22例,均接受恩度联合FOLFOX4方案的治疗,每28 d为1个疗程,用药1个疗程即可评价毒性,2个疗程后方可评价疗效。结果 34例可评价疗效患者治疗2~6周期后完全缓解(CR):1例(5.26%),部分缓解(PR):10例(23.5%),稳定(SD):12例(35.3%),进展(PD):13例(38.2%),客观有效率(RR)为26.5%(9/34),疾病控制率(DCR)为61.8%(21/34)。中位疾病进展时间(mTTP)为7.2个月。主要毒副反应为骨髓抑制、消化道反应、神经毒性,无4级毒副反应,无心律失常及出血发生。结论 YH-16联合FOLFOX4方案治疗晚期胃肠道肿瘤疾病控制率(DCR)较好,且不良反应轻,尤其以大肠癌效果明显,是一种安全而有效的治疗方案。 |
| 关 键 词： | 胃肠道肿瘤 血管人内皮抑制素 化学治疗 |
Clinical study of Rh-endostatin(RH-16)combinedwith FOLFOX4 in the treatment of advanced gastrointestinal cancer |
|
| WANG Mei-xing,CAI Yang,FAN Hong-bin,DAI Yue-di,TAO Li,ZUO Li. Clinical study of Rh-endostatin(RH-16)combinedwith FOLFOX4 in the treatment of advanced gastrointestinal cancer[J]. Journal of Clinical Medicine in Practice, 2011, 15(5): 8-11,14 | |
| Authors: | WANG Mei-xing CAI Yang FAN Hong-bin DAI Yue-di TAO Li ZUO Li |
| Affiliation: | WANG Mei-xing,CAI Yang,FAN Hong-bin,DAI Yue-di,TAO Li,ZUO Li(Cancer Hospital Affiliated to Fudan University,Minhang Branch,Shanghai,200240) |
| Abstract: | Objective To investigate the short term efficacy and safety of recombinant human endostatinin(Endostar,YH-16) combined with FOLFOX4 in the treatment of advanced gastrointestinal cancer.Methods 40 patients with histopathologically or cytologically proven advanced gastrointestinal tumor,among whom 18 are gastric carcinoma and 22 are colonrectal cancer,received endostatinin plus FOLFOX4,28 day course.Toxicity was evaluated after one course and efficacy was investigated after two courses.Results Among the 34 as... |
| Keywords: | gastrointestinal cancer recombinant human endostatin chemotherapy |
| 本文献已被 CNKI 万方数据 等数据库收录！ | |